Business
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antiviralsKELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp.
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antiviralsKELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for Compositions and Methods For Enhanced Delivery Of Antiviral Agents will be issued to the Company on April 26, 2022.\"This will be our 25th patent granted worldwide and another validation of the versatility of our DehydraTECH drug delivery technology,\" said Chris Bunka, CEO of Lexaria. \"This new patent adds to our existing suite of granted patents in the EU, the U.S., India, Japan and Australia, and continues to build value for Lexaria shareholders and clients.\"Lexaria previously announced that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19/SARS-CoV-2 virus using an in vitro screening assay in infected cells in study VIRAL-C21-3. Lexaria separately demonstrated that antiviral drugs processed with DehydraTECH were able to reach peak blood concentration levels that were double those of non-DehydraTECH-processed; and overall volumes of drug delivered into bloodstream were up to triple the amount compared to non-DehydraTECH-processed drugs.As evidenced with other drugs that Lexaria has investigated, the award of intellectual property protection is a key step towards ultimately monetizing Lexaria's revolutionary DehydraTECH drug delivery technology. This is Lexaria's 25th granted patent and the 10th granted in the U.S. Lexaria continues to file new patent applications as its research and development programs uncover new discoveries.About Lexaria Bioscience Corp.Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formula...